Medpace Holdings, Inc. (MEDP) Operating Margin
- Operating margin · 12 months: Value 20.97%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 20.97% | Operating income / revenue. Period ending 2026-06-30. $583.40M ÷ $2.78B × 100 ≈ 20.97% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 583.40M USD | Operating Income (Loss) |
| Revenue | 2.78B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | |
| Selling, general and administration | 189.02M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $583.40M | $2.78B | (m) | (m) | $189.02M | 20.97% |
| 2026-03-31 | $562.91M | $2.68B | (m) | (m) | $187.58M | 21.02% |
| 2025-12-31 | $534.93M | $2.53B | (m) | (m) | $197.56M | 21.14% |
| 2025-09-30 | $507.04M | $2.36B | (m) | (m) | $198.08M | 21.50% |
| 2025-06-30 | $477.51M | $2.23B | (m) | (m) | $199.21M | 21.40% |
| 2025-03-31 | $456.32M | $2.16B | (m) | (m) | $194.00M | 21.16% |
| 2024-12-31 | $446.87M | $2.11B | (m) | (m) | $180.18M | 21.19% |
| 2024-09-30 | $408.81M | $2.07B | (m) | (m) | $177.26M | 19.74% |
| 2024-06-30 | $381.45M | $2.03B | (m) | (m) | $169.46M | 18.79% |
| 2024-03-31 | $354.69M | $1.96B | (m) | (m) | $167.41M | 18.07% |
| 2023-12-31 | $336.82M | $1.89B | (m) | (m) | $161.35M | 17.86% |
| 2023-09-30 | $325.94M | $1.78B | (m) | (m) | $152.24M | 18.30% |
| 2023-06-30 | $318.86M | $1.67B | (m) | (m) | $146.25M | 19.06% |
| 2023-03-31 | $300.70M | $1.56B | (m) | (m) | $140.06M | 19.24% |
| 2022-12-31 | $278.70M | $1.46B | (m) | (m) | $131.40M | 19.09% |
| 2022-09-30 | $257.12M | $1.37B | (m) | (m) | $125.66M | 18.71% |
| 2022-06-30 | $233.01M | $1.29B | (m) | (m) | $118.29M | 18.11% |
| 2022-03-31 | $215.22M | $1.21B | (m) | (m) | $112.05M | 17.74% |
| 2021-12-31 | $198.62M | $1.14B | (m) | (m) | $108.42M | 17.39% |
| 2021-09-30 | $198.75M | $1.09B | (m) | (m) | $103.14M | 18.18% |
| 2021-06-30 | $191.46M | $1.03B | (m) | (m) | $97.89M | 18.62% |
| 2021-03-31 | $179.14M | $955.01M | (m) | (m) | $92.77M | 18.76% |
| 2020-12-31 | $167.04M | $925.92M | (m) | (m) | $92.16M | 18.04% |
| 2020-09-30 | $148.17M | $896.13M | (m) | (m) | $91.04M | 16.53% |
| 2020-06-30 | $131.74M | $882.00M | (m) | (m) | $97.36M | 14.94% |
| 2020-03-31 | $136.87M | $891.11M | (m) | (m) | $99.06M | 15.36% |
| 2019-12-31 | $127.26M | $860.97M | (m) | (m) | $95.25M | 14.78% |
| 2019-09-30 | $121.81M | $823.20M | (m) | (m) | $94.55M | 14.80% |
| 2019-06-30 | $118.74M | $786.21M | (m) | (m) | $84.04M | 15.10% |
| 2019-03-31 | $106.82M | $742.25M | (m) | (m) | $80.99M | 14.39% |
| 2018-12-31 | $101.05M | $704.59M | (m) | (m) | $75.68M | 14.34% |
| 2018-09-30 | $85.82M | $625.16M | (m) | (m) | $71.95M | 13.73% |
| 2018-06-30 | $76.10M | $556.55M | (m) | (m) | $69.95M | 13.67% |
| 2018-03-31 | $69.03M | (m) | (m) | (m) | $64.20M | (m) |
| 2017-12-31 | $64.86M | $436.15M | (m) | (m) | $63.36M | 14.87% |
| 2017-09-30 | $62.31M | $431.71M | (m) | (m) | $63.30M | 14.43% |
| 2017-06-30 | $57.73M | $428.87M | (m) | (m) | $63.08M | 13.46% |
| 2017-03-31 | $55.56M | $428.61M | (m) | (m) | $63.15M | 12.96% |
| 2016-12-31 | $52.49M | $421.58M | (m) | (m) | $61.51M | 12.45% |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $33.29M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $27.04M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $20.56M | $359.06M | (m) | (m) | $57.00M | 5.73% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |